FDA grants Neurelis intranasal diazepam IND
NRL-1 is a proprietary formulation of diazepam delivered via a commercially available nasal sprayer, and is being developed for the management of patients who require intermittent use of
BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey, US.